Dual PI3K/mTOR inhibitor NVP-BEZ235 decreases the proliferation of doxorubicin-resistant K562 cells

Acute myelogenous leukemia (AML) is frequently accompanied by a poor prognosis. The majority of patients with AML will experience recurrence due to multiple drug resistance. Our previous study reported that targeting the mTOR pathway may increase cell sensitivity to doxorubicin (Doxo) and provide an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Med Rep
Main Authors: Li, Jie, Wang, Xiaozi, Ma, Chuanbao, Xu, Shasha, Xu, Mengyao, Yang, Jie, Wang, Ruicang, Xue, Liying
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2021
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7930928/
https://ncbi.nlm.nih.gov/pubmed/34223631
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mmr.2021.11940
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados